# Sarepta Therapeutics

Elevidys — AAV rh74 micro-dystrophin.

Source: https://en.bioecon.ru/companies/sarepta-therapeutics/
Updated: 2026-06-24

- Country: United States
- Ticker: SRPT

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 1980 | https://umbrex.com/resources/company-profiles/sarepta-therapeutics/ |
| Headquarters | Cambridge, Massachusetts, United States | https://investorrelations.sarepta.com/static-files/6a6f93ae-4952-4aea-93e7-476f0b17c832, https://umbrex.com/resources/company-profiles/sarepta-therapeutics/ |
| Headcount | approximately 843 to 899 employees (as of 2026) | https://investorrelations.sarepta.com/static-files/6a6f93ae-4952-4aea-93e7-476f0b17c832 |
| Revenue | $1,864.3 million (total net product revenue for 2025); $328.7 million (total net product revenue for Q2 2026) | https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-reports-preliminary-fourth-quarter-and-full-year-2025, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-second-quarter-2026-financial, https://investorrelations.sarepta.com/node/24996/pdf, https://investorrelations.sarepta.com/static-files/6a6f93ae-4952-4aea-93e7-476f0b17c832 |
| Regulatory approval | FDA accelerated approval (June 2023) and traditional/expanded approval (June 2024) for Elevidys in the U.S.; approval in Japan (May 2025) | https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene, https://investorrelations.sarepta.com/static-files/6a6f93ae-4952-4aea-93e7-476f0b17c832 |
| Production site | Catalent facilities in Harmans, Maryland (BWI) and Baltimore, Maryland | https://endpoints.news/catalents-oft-maligned-gene-therapy-plant-is-manufacturing-sareptas-elevidys/, https://investorrelations.sarepta.com/static-files/6a6f93ae-4952-4aea-93e7-476f0b17c832 |
| Capacity | Relies on contract manufacturing partners (Catalent and Aldevron); manufacturing capacity and supply chain subject to operational requirements and agreements with partners [medium confidence] | https://endpoints.news/catalents-oft-maligned-gene-therapy-plant-is-manufacturing-sareptas-elevidys/, https://investorrelations.sarepta.com/static-files/6a6f93ae-4952-4aea-93e7-476f0b17c832, https://umbrex.com/resources/company-profiles/sarepta-therapeutics/ |

Independent sources: endpoints.news, investorrelations.sarepta.com, umbrex.com

## Technologies

- [In-vivo gene therapy: AAV and lentiviral vectors](https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/)
- [Nucleic acid therapeutics (oligonucleotides)](https://en.bioecon.ru/technology/nucleic-acid-therapeutics/)
- [Personalized & regenerative medicine](https://en.bioecon.ru/technology/personalized-regenerative-medicine/)